HomeHNSPF • OTCMKTS
add
Hansoh Pharmaceutical Group Company Ltd
Previous close
$1.88
Year range
$1.50 - $1.88
Market cap
112.39B HKD
P/E ratio
-
Dividend yield
-
Primary exchange
HKG
In the news
Financials
Income Statement
Revenue
Net income
| (CNY) | Jun 2024info | Y/Y change |
|---|---|---|
Revenue | 3.25B | 44.21% |
Operating expense | 1.66B | 12.83% |
Net income | 1.36B | 111.47% |
Net profit margin | 41.90 | 46.66% |
Earnings per share | — | — |
EBITDA | 1.40B | 131.62% |
Effective tax rate | 12.59% | — |
Balance Sheet
Total assets
Total liabilities
| (CNY) | Jun 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 23.50B | -0.16% |
Total assets | 31.67B | -0.84% |
Total liabilities | 3.77B | -51.47% |
Total equity | 27.90B | — |
Shares outstanding | 5.93B | — |
Price to book | 0.40 | — |
Return on assets | 10.25% | — |
Return on capital | 11.58% | — |
Cash Flow
Net change in cash
| (CNY) | Jun 2024info | Y/Y change |
|---|---|---|
Net income | 1.36B | 111.47% |
Cash from operations | 1.34B | 134.03% |
Cash from investing | 1.18B | 127.37% |
Cash from financing | -2.10B | -8,216.31% |
Net change in cash | 407.85M | -60.50% |
Free cash flow | 778.25M | 121.05% |
About
Hansoh Pharmaceutical Group Company Limited is a pharmaceutical company that manufactures and sells various types of medicine in mainland China. It was founded in 1995 in Lianyungang, Jiangsu Province, China, by Zhong Huijuan, who is the company's chair. Zhong and her family own 66% of the company. It is the largest psychotropic drug producer in China.
Hansoh Pharmaceutical had an initial public offering on the main board of the Hong Kong Stock Exchange on 14 June 2019.
In August 2022, it was announced that the company's stock would be added to the Hang Seng Index. Wikipedia
Founded
1995
Website
Employees
9,099
